United States Antimony Corporation (NYSE American: $UAMY) has strengthened North America’s tungsten supply chain with the US$5 million acquisition of the Fostung property, 50 single-cell mining claims covering 1,114 hectares, approximately 70 kilometers west-southwest of Sudbury,

🎙️ VP of Global Sales Doug Heath and VP of Marketing Anna Turkington discuss Intelligent Bio Solutions’ growth outlook, global expansion, and strategy. Tune in: hubs.li/Q03v6s8v0 🇺🇸 #NASDAQ: $INBS

Unicycive Therapeutics (Nasdaq: UNCY) today announced receipt of a Complete Response Letter (CRL) from the U.S. FDA regarding its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), an investigational treatment for hyperphosphatemia in patients with chronic kidney

United States Antimony Corporation (NYSE American: UAMY) announced that the company’s shares are being dual listed on the NYSE Texas Exchange as of July 1, 2025, maintaining its primary NYSE American listing under the same “UAMY” ticker symbol. United States Antimony Corporation NYSE: UAMY is a B2i Digital

Maxim Group analysts released a research note on Unicycive Therapeutics (Nasdaq: $UNCY) following the company’s Complete Response Letter (CRL) from the FDA regarding its oxylanthanum carbonate (OLC) application. Unicycive Therapeutics Therapeutics is a B2i Digital Featured Company. View

Vycor Medical, Inc. (OTCQB: VYCO) announced the publication of a new peer-reviewed clinical study on its NovaVision division’s NeuroEyeCoach training program, demonstrating significant benefits for stroke patients recovering from visual disorders in both home and clinic settings.

Today we announced that we regained compliance with the Nasdaq Stock Market minimum bid price requirement. Learn more: ir.unicycive.com/news/detail/10…

Kolibri CEO Wolf Regener on Oil Price Volatility, Drilling Efficiencies, and Inclusion in the Russell 2000 In a new one-on-one conversation with B2i Digital’s Charlie Napolitano, KOLIBRI Energy – NASDAQ:KGEI | TSX:KEI (Nasdaq: KGEI | TSX: KEI) President & CEO Wolf Regener explains how disciplined

OS Therapies (NYSE-A: OSTX) announced a series of clinical and regulatory milestones today. The company has secured an End-of-Phase 2 meeting with the U.S. Food and Drug Administration on 27 August 2025 to discuss a rolling Biologics License Application for its lead candidate,

Heidmar Maritime Holdings Corp. (NASDAQ: $HMR) is well-positioned to capitalize on investment opportunities in older MR tankers and technical management acquisitions, as asset values have declined significantly from their 2024 highs. Heidmar Inc. is a B2i Digital Featured

Intelligent Bio Solutions (Nasdaq: INBS) announced that it will present Pharmacokinetic (PK) study data at the Association for Diagnostics and Laboratory Medicine (ADLM) 2025 Clinical Lab Expo in Chicago, July 27–31, confirming that fingerprint-sweat samples closely track codeine

Alternus Clean Energy (OTCQB: $ALCE, ACLEW) announced its official entry into the UK renewable energy market. This strategic expansion, undertaken in partnership with microgrid innovator Hover Energy, LLC, represents a significant milestone in the company’s growth and geographic

Huge congrats! 🎉 "Shelter Me: The Cancer Pioneers," featuring OS Therapies' OST-HER2, earned 2 Daytime Emmy nominations! 🏆 This film showcases the drive for new cancer treatments. Support for the film champions vital medical innovation as we advance toward BLA for OST-HER2

Our VP of Product Development Peter Passaris and VP of Global Quality and Operations Callistus Sequeira discuss our new language integrations for the drug screening reader and key company updates. Watch: hubs.li/Q03w_tbh0 🇺🇸 $INBS #NASDAQ

OS Therapies (NYSE-A: OSTX) announced that it has closed its previously announced warrant-exercise inducement and exchange offer, raising $4.2 million in gross proceeds and extending its cash runway through 2026, beyond the September 2026 sunset of the Rare Pediatric Disease

$INBS expands non-invasive testing portfolio with the SmarTest Sweat Patch. The Patch enables continuous #noninvasive drug detection for 7-10 days, complementing INBS's existing drug screening system & supporting short & long-term detection needs. hubs.ly/Q03w_Vc20 #NASDAQ

United States Antimony Corporation (NYSE, NYSE Texas: UAMY) announced an extensive update on its global and domestic procurement strategy, detailing new contracts and mine developments that will supply feedstock to its Thompson Falls, Montana, and Madero, Mexico smelters.

Kidney disease develops quietly, with few noticeable symptoms in its early stages. We’re determined to improve outcomes for those living with #ChronicKidneyDisease (CKD). Discover how: unicycive.com/our-approach/

Intelligent Bio Solutions (Nasdaq: INBS) announced the addition of the SmarTest® Patch, an extended-duration wearable that continuously detects drugs in sweat for seven to ten days, expanding its portfolio of non-invasive, sweat-based testing technologies. Intelligent Bio

Global unity in the face of uncertainty, with $OSTX CEO Paul Romness & EVERSANA VP of Business Development Farah Ahmad. Tune in to an impressive discussion during #BIO2025 about our relationship with EVERSANA as we advance clinical-stage programs: bit.ly/4kR4sNQ